Group items tagged

Global consumer healthcare company Haleon has launched a new centre of excellence for a global leader in consumer health which will bring together world leading academics in human behaviour and frontline healthcare professionals including community pharmacists. Unveiled at the International Pharmaceutical Federation (FIP) Congress in 'sunny' Seville, Spain on September 20, the Centre will operate as a community of healthcare professionals and specialists in behavioural science, health psychology and the social sciences to solve some of the most pressing everyday health challenges. Named the Centre for Human Sciences (CHS) the initiative will be the first major programme for healthcare professionals since the Haleon's launch on July 18 as an independent, global leader in consumer health. The Centre's mission is to support practising health professionals - pharmacists, pharmacy assistants and dental professionals - in serving their patients and communities. Combining science with deep human understanding, CHS will bring expertise in physiology together with human sciences to deliver real world-solutions and tangible interventions, resulting in measurable improvements in health outcomes through sustained behavioural change. The Centre is facilitated by Robert Horne, professor of Behavioural Medicine at UCL School of Pharmacy, who started his career as a practising pharmacist but later chose to become a behavioural scientist when he saw an opportunity to address issues around psycho-social factors that acted as a hindrance in pharmacy practice. Speaking to me in an exclusive three-way conversation alongside Tess Player, the global head of healthcare professional & health influencer marketing at Haleon, on the sidelines of the FIP Congress 2022, Prof Horne expanded on what the Centre was all about and how it would work. "We've got some good ideas, but it's not a pre-filled prescription that we're going to deliver at scale from the start. What Haleon is t

The results of a national NHS staff survey, published recently, revealed that frontline healthcare workers are facing record levels of discrimination at work, with 58,000 respondents reporting that they experienced "unacceptable" levels of unwanted sexual behaviour from the public last year. Concerningly, 8.67 per cent of 675,140 NHS workers who responded to the poll said they suffered sexual harassment from patients, patients' relatives, or other members of the public in 2023. Particularly, ambulance staff were affected, with nearly 25 per cent of staff reporting unwanted sexual behaviour from the public last year. According to the survey findings, 3.84 per cent of staff also encountered unwanted sexual behaviour from their colleagues. Dr Navina Evans, Chief Workforce, Training and Education Officer, described the survey results as "very distressing" and said that "such conduct should not be tolerated in the NHS." On the positive side, more NHS workers reported being happier at work and experiencing less burnout than before. Over half of the participants stated they look forward to coming to work, the highest number since 2020, as per the NHS. Dr Evans attributed this improvement to initiatives such as flexible working hours, clinical support squads to help menopausal women at work, and human resources stay advocates.

cognitive behavioural therapy cbt

The National Pharmacy Association (NPA)'s Health Education Foundation (HEF) has funded a major study that aimed to test the SPUR tool and evaluate how effective it was at measuring medicines adherence. The study has been published in the British Medical Journal Open. Dr Joshua Wells, a fourth year PhD candidate at Kingston University, who was awarded the NPA bursary, was the lead researcher for the SPUR UK study, under the guidance of Professor Reem Kayyali. Created by Observia, a health research group, SPUR is a self-assessment questionnaire which helps to detect a patient's risk of medicine non-adherence and aims to accurately articulate the reasons for health behaviour. As well as funding from HEF, the study was made possible via a partnership with Kingston University and Kingston Hospital. HEF chair of Trustees, Dr Ian Cubbin, said: "We are delighted that NPA's Health Education Foundation has played a part in such an important study. This research could lead ultimately to a far more personalised, tailored approach to medicines optimisation - recognising that people's medicines behaviour can be highly individual to them."

The Medicines and Healthcare products Regulatory Agency (MHRA) has reminded healthcare professionals prescribing aripiprazole to alert patients about its possible side effects, following a rise in the number of reports of gambling disorder associated with the drug. Patients taking aripiprazole, which is used for the treatment of schizophrenia and bipolar disorder, are at risk of developing unusual urges or cravings that they cannot resist, including behaviours such as addictive gambling, excessive eating or spending, or an abnormally high sex drive. The regulator has received 69 reports of gambling or gambling disorder suspected to be caused by aripiprazole in the last 14 years via the Yellow Card Scheme, out of which 32 were received between 1 January and 31 August this year. Alison Cave, MHRA Chief Safety Officer, said: "The number of reports for suspected gambling and other impulsive behaviours associated with aripiprazole are small in comparison to the frequency with which it is prescribed, but the consequences for any patient developing these conditions can be significant."

Increased demand and shortages of lateral flow tests are pushing staff at pharmacies to bear the brunt from frustrated customers who are unable to get their free lateral flow tests, Daily Mail reported. Some Britons claimed that they have been unable to get lateral flow tests at their local pharmacies for up to a fortnight while some pharmacies were forced to put up sign warning stating they have run out of free tests. Given the patchy supply of test kits, pharmacy bosses warned that staff are facing 'unfair' and 'abusive' behaviour by customers, the newspaper reported.Dr Leyla Hannbeck, chief executive of the Association of Independent Multiple Pharmacies (AIMP), told the newspaper: "Up until yesterday the supply to pharmacies was still patchy. The past few days the situation has not improved. "Pharmacies are having to put up with a lot of abuse and aggressive behaviours by members of the public because of this situation which is unfair. "The demand is still very high now because the governments guidelines put a lot of emphasis on testing as a key out of self isolation, so naturally as Omicron cases are high people are reliant on tests to get on with daily life."

Violent and abusive behaviour against pharmacists is impacting on recruitment and retention of staff in the sector, according to the Pharmacists' Defence Association (PDA). The trade union for pharmacists told BBC Breakfast TV on Wednesday (May 8) that its members have continuously raised workplace safety concerns due to an alarming rise in the incidents of abuse and violence against pharmacy staff. The PDA union has been calling for adequate risk assessments and preventative safety measures to be put in place in pharmacies whist adopting a zero-tolerance approach to violence and abuse. With several significant and worrying incidents involving PDA members, including a pharmacist being threatened with a knife recently, further research was conducted in April 2022 to establish the extent and impact of such behaviour on pharmacists. Forty-four per cent of the respondents in the survey reported that they or someone that they worked with had experienced physical or violent abuse in the last month.

The Department of Health and Social Care (DHSC) has introduced a new 'swap to stop' scheme to encourage one million smokers to swap cigarettes for vapes in England. As part of the world-first national scheme, almost 1 in 5 of all smokers in England will be provided with a vape starter kit alongside behavioural support to help them quit the habit as part of a series of new measures to help the government meet its ambition of being smokefree by 2030 - reducing smoking rates to 5% or less. Local authorities will also be invited to take part in the scheme later this year and each will design a scheme which suits its needs, including deciding which populations to prioritise. Health Minister Neil O'Brien announced on Tuesday (11 April) that pregnant women will be offered financial incentives to help them stop smoking. This will involve offering vouchers, alongside behavioural support, to all pregnant women who smoke by the end of next year. The government will also consult on introducing mandatory cigarette pack inserts with positive messages and information to help people to quit smoking. It has also announced a formation of new 'illicit vapes enforcement squad' to regulate and tackle the sales of illegal vapes to under 18s.

Prime minister Boris Johnson announced on Wednesday (January 19) that restrictions re-imposed in England last month would be lifted by from next Thursday (January 27). In the latest development, the government has decided to end the guidance on working from home, asking employers to make adequate arrangements to return safely to work. From the start of next Thursday, mandatory certification based on vaccines and tests will end, however, organisations can still choose to use the NHS Covid Pass voluntarily. Besides, the legal mandate to wear face masks will go away from next week. Making a statement to the House of Commons on Covid-19, he said that infection levels are falling in England mainly because of the country's "extraordinary booster campaign". He noted more than 36 million Covid-19 booster jabs had been delivered, with over 90 percent of over-60s now given a third dose. "Our scientists believe it is likely that the Omicron wave has now peaked nationally," Johnson added, while cautioning "the pandemic is not over". "I encourage everyone across the country to continue with all the cautious behaviours that we know help to keep each everybody safe."

The Centre for Pharmacy Postgraduate Education (CPPE) has announced launch of the new e-learning programme on controlled drugs in chronic pain to support patients. The programme launched on Monday (January 17), aims to support pharmacy professionals to develop the knowledge, skills and behaviours to support patients to use prescribed controlled drugs safely with a focus on chronic pain. The new programme will open new opportunities for pharmacy professionals to improve patient care, in relation to the safe prescribing and use of controlled drugs.

An independent committee at the National Institute for Health and Care Excellence (NICE) has developed a menu of options to treat depression in adults. The first guideline to identify, treat and manage depression has been created after looking at the evidence of treatment on various aspects of depression. The guideline allows patients to select the best suited cure for them through a shared decision-making process between them and their healthcare practitioner. Patients with less severe depression can choose a first-line treatment option from the menu, such as cognitive behavioural therapy (CBT), exercise, counselling or psychotherapy. Similarly, those with a severe depression can select from a range of psychological interventions and antidepressant medication. As per data released by the Office of National Statistics, around 17 per cent of people aged 16 years and over in Great Britain experienced some form of depression in summer 2021, higher than the previous year.

The PDA has raised concerns over the 'deliberate breaches' of the NHS contract by some community pharmacy businesses, saying that it may cause harm to patients and damage the reputation of the profession. The organisation said concerned pharmacists have revealed to them that some businesses are now explicitly saying that if locums will not agree to work for less than a so-called 'maximum' hourly rate, the business will close the pharmacy for either part of, or the whole day. Some of these full or part-day closures are being communicated significantly in advance of the actual day, it added. The union further alleged that several pharmacy businesses seem to have simultaneously implemented identical so-called 'maximum rates' in what could be an anti-competitive behaviour.

The Pharmacists' Defence Association (PDA) has advised its member to check their understanding of what activities can legitimately take place when no RP is signed in at the pharmacy or the absence provisions are used. The advisory to its member was followed after noticing a considerable talk on social media about compliance with the Responsible Pharmacist (RP) regulations which also included unauthorised activity occurring when no RP is signed in. "There have been comments made that some pharmacists and pharmacy team members may fear repercussions from challenging or whistle-blowing about such behaviour," PDA said. "To assist members with the interpretation of the RP regulations, the PDA has made available a legal briefing note about the RP regulations produced by a specialist pharmacy regulation law firm." It further added: "Non-compliance with the regulations by pharmacy teams should be reported to the pharmacy superintendent."

Consumer health company Haleon, formerly known as GSK, claims that pain's emotional and life impact has grown by nearly 25 per cent in the past decade. The company has launched a campaign #ListenToPain to personalise patients' pain management through a series of practical tools and resources. The campaign was introduced on 28 September which focused on enabling the HCPs to maximise their time with patients and understand their pain experience - providing them with an effective treatment plan. The new data has been obtained through the fifth edition of the Haleon Pain Index (HPI). This social study measured the impact of individuals' everyday lives, their health, their feelings, their emotions, motivations and behaviours. They have spoken to more than 87,000 people around the world since their first edition in 2014 - HPI 1 (The State of Pain), which later progressed over the years from HPI 2 (Impact of Pain) in 2017, then HPI 3 (Managing Pain) in 2018, to HPI 4 (Treatment Journey), and finally HPI 5 (Pain and Inclusivity) in 2023.

The Royal Pharmaceutical Society (RPS) Wales and the Association of the British Pharmaceutical Industry (ABPI) co-hosted a drop-in session to inform members of the Senedd (MSs) about the action taken by pharmacists to make medicines use more sustainable. At a 'drop-in' session the ABPI, RPS members and staff had the opportunity to speak to a number of MSs from all political parties. "With medicines accounting for around 25 per cent of the NHS carbon emissions, conversations were based around the key recommendations to reverse this from the RPS' policies on sustainability," said RPS. The three key themes emphasised in all discussions were- the need to educate the public and change behaviours to avoid stockpiling medicines; How the clinical skills of prescribing pharmacists can be used for appropriate de-prescribing and switching patients to low carbon options; and importance of tackling waste. RPS Wales Director Elen Jones said: "It was fantastic to see how interested and engaged the politicians were around these important issues. By the end of our conversations, they all clearly understood and supported the importance of pharmacy leadership in this area, as well as the need for the link between climate change and medicines to be better understood by patients.

More than half of people (52%) do not feel confident in treating backache and less than half (44%) uses community pharmacists' advice as their first step on self-treatable conditions, a self-care attitudes 2022 survey has revealed. PAGB, the consumer healthcare association, surveyed over 2,000 adults across the UK about their attitudes towards self-care and access to health services. According to the survey, the public is in favour of self-care but many people lack the confidence and knowledge to care for the most common self-treatable conditions including backaches, headaches, diarrhoea and constipation. Four in five respondents (79%) said that people should take more responsibility for their own health and three-quarters (73%) believe that the NHS should make self-treatment easier. Behaviours around the current use of pharmacy varied - with less than half (44%) using community pharmacists as their first step in in getting advice on self-treatable conditions - but longer term attitudes were encouraging, with 69% supporting the idea of GPs being able to make referrals to pharmacists. Respondents also supported expanding the role of pharmacists so that their skills can be better utilised.

The Pharmaceutical Defence Association (PDA) has urged health ministers of the UK to take a strict and necessary action against the unnecessary closures of pharmacy. Concerned over the rising number of pharmacy closures, PDA has written an open letter to health secretary Steve Barclay; Robin Swann, health minister for Northern Ireland; Eluned Morgan, minister of health and social services for Wales; and Humza Yousaf, the Scottish health secretary. In its letter, PDA said: "The minister of health must now ensure the regulation of poor business behaviours and be prepared to take over rogue pharmacies, however large their corporate owner may be. If patients' access to NHS services is to be protected from the consequences of avoidable full or part-day pharmacy closures." The association believes it is only a matter of time before serious harm to patients' health will be caused by the decisions of mainly large chains of pharmacies to close some of their branches for all or part of a day, instead of engaging an available pharmacist to cover their agreed opening hours. "While a small number of unforeseen closures have always occurred from time to time in pharmacies for genuine reasons, the indiscriminate scale at which closures have now become commonplace seems to have evolved over the last 20 months."

Colonis, a subsidiary company of the Clinigen Group has received the Medicines and Healthcare products Regulatory Agency (MHRA) approval for Melatonin 1mg/ml Oral Solution for sleep onset insomnia in children and adolescents aged 6-17 years with attention-deficit hyperactivity disorder (ADHD). Clinical evidence demonstrates that Melatonin has the potential to decrease sleep latency and increase sleep efficiency in children with ADHD and chronic sleep onset insomnia. Children with ADHD are statistically more likely to have sleep onset insomnia than non-ADHD children. The prevalence of sleep onset insomnia in children with ADHD ranges from 25%-50%. Sleep onset insomnia in children with ADHD can affect their mood, attention, behaviour and school performance. Henno Welgemoed, Director of Medical Affairs at Colonis said: "We welcome the MHRA's approval for a condition that negatively affects the quality of life for children and adolescents diagnosed with ADHD and increases the burden for support networks."

Pharmacists are a vital member of the multidisciplinary team (MDT) supporting older people to manage their pain. The pharmacist is uniquely positioned to holistically review drug interactions and potential risks associated with each patient's medication and has the expertise to suggest alternative treatment options to reduce the risks associated with polypharmacy or unwanted side effects caused by other medications. Chronic pain The International Association for the Study of Pain defines pain as an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage. Although universally experienced by everyone, the perception of pain is a deeply personal experience influenced by biological, psychological, and social factors, and constitutes an essential behavioural feedback mechanism aimed at protecting us from harm. Pain may be perceived as either acute or chronic. Chronic pain, defined as pain that persists longer than the normal healing time, constitutes a substantial healthcare burden, affecting approximately 20 per cent of people worldwide and accounts for 15-20 per cent of physician consultations. Chronic pain is often associated with disrupted mood and sleep, substance misuse and other chronic conditions. Additionally, comorbidities of chronic pain may also lead to complex medication regimens that increase the risks of adverse drug interactions and unwanted side effects.

The NHS Diabetes Prevention Programme, which was introduced in England in 2016, is helping hundreds of thousands of people to lead healthier lives. People with pre-diabetes are being identified and offered a nine-month behaviour change programme that supports healthier diet and exercise choices to reduce their risk of developing diabetes. A study funded by the National Institute for Health and Care Research (NIHR) has found a significant reduction in diabetes risk among patients who had been referred to the NHS programme. Three years after their referral, the participants were 20 per cent less likely to have type 2 diabetes than a similar person who was not included in the programme, the evaluation revealed.